XM n’offre pas ses services aux résidents des États-Unis d’Amérique.

Wall Street futures muted ahead of business survey data



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>US STOCKS-Wall Street futures muted ahead of business survey data</title></head><body>

For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window

Spirit Aero up following report of Boeing nearing buyout deal

Sarepta surges on expanded use of gene therapy

Gilead gains after long-acting HIV drug trial success

Futures: Dow, S&P 500, Nasdaq flat

Updated at 7:29 a.m. ET

By Lisa Pauline Mattackal and Ankika Biswas

June 21 (Reuters) -U.S. stock index futures were little changed on Friday as megacap tech and chip stocks lost ground, with investors awaiting manufacturing and services sectors surveys for more clues on the health of the world's largest economy.

The S&P 500 .SPX crossed the 5,500 point milestone during Thursday's session, however, both the benchmark index and the tech-heavy Nasdaq .IXIC closed lower as megacap stocks pulled back.

AI chip firm Nvidia NVDA.O dropped 1.4% in premarket trading on Friday, after losses in the previous session saw its market valuation fall back below that of Microsoft MSFT.O.

Semiconductor stocks Qualcomm QCOM.O, Micron Technology MU.O and Arm Holdings ARM.O were down between 1% and 2%, while megacaps such as Microsoft and Meta Platforms META.O were down around 0.3% each.

Wall Street's bumper gains since the final leg of 2023 has been primarily driven by the likes of Nvidia and a handful of other heavily weighted stocks linked to artificial intelligence. Analysts, however, have flagged whether the strong increase in their valuations is sustainable.

Investors are also assessing a string of weakening economic data and commentary from the U.S. Federal Reserve officials that interest rates could remain higher for longer if there is no consistent improvement in inflation numbers.

Later in the day, focus will be on flash S&P PMI readings, that are expected to fall slightly, but remain above the 50 level that shows activity is still expanding.

"Any unexpected slowdown in the U.S. economy could spark some jitters ... but investors will be hoping to see a moderation in price pressures, which would be positive for risk sentiment," said Raffi Boyadjian, lead investment analyst at forex broker XM.

Friday's session will also mark the expiry of quarterly derivatives contracts tied to stocks, index options and futures, also known as "triple witching".

"With Wall Street hit by profit taking after almost uninterrupted gains during June, there is a risk of some further volatility on Friday because of triple witching," Boyadjian said.

All three major Wall Street stock indexes are set to close the week higher, as is the small-cap focused Russell 2000 .RUT.

Money markets are pricing in a 58% chance of a 25-basis point interest rate cut at the Fed's meeting in September, and still expect about two rate cuts this year, according to LSEG's FedWatch data. FEDWATCH

At 7:29 a.m. ET, Dow e-minis 1YMcv1 were up 7 points, or 0.02%, S&P 500 e-minis EScv1 were down 1.75 points, or 0.03%, and Nasdaq 100 e-minis NQcv1 were up 2.25 points, or 0.01%.

Spirit AeroSystems SPR.N jumped 4.2% following a Reuters report that Boeing BA.N is nearing a deal to buy back the airplane parts supplier after months of talks.

Drugmaker Gilead GILD.O jumped 2.9%, extending gains from Thursday as a late-stage study showed its long-acting injectable drug was more effective in preventing HIV infection in women compared to its existing daily pill Truvada.

Sarepta Therapeutics SRPT.O soared 37.1% after the U.S. Food and Drug Administration allowed the expanded use of the company's gene therapy for patients with Duchenne muscular dystrophy aged four and older.



Reporting by Lisa Mattackal and Ankika Biswas in Bengaluru; Editing by Shounak Dasgupta

</body></html>

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques